WAM
CORT icon

Wakefield Asset Management’s Corcept Therapeutics CORT Stock Holding History

Wakefield Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-21,391
Closed -$2.44M – 211
2025
Q1 		$2.44M Buy
21,391
+1,684
+9% +$102K 0.74% 41
2024
Q4 		$993K Buy
+19,707
New +$1.03M 0.34% 101

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wakefield Asset Management's CORT Position: Q2 2025 in Review

Wakefield Asset Management sold out of Corcept Therapeutics (CORT) in Q2 2025, closing a stake of 21,391 shares — an estimated $2.44M sold.

Wakefield Asset Management first reported a position in CORT in Q4 2024 and held it in 2 quarters. The position peaked at $2.44M in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2025.

  • Wakefield Asset Management reported no remaining Corcept Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Wakefield Asset Management sold 21,391 Corcept Therapeutics shares in Q2 2025, an estimated $2.44M.
  • Wakefield Asset Management first reported a position in Corcept Therapeutics in Q4 2024 and held it in 2 quarters.
  • Wakefield Asset Management's Corcept Therapeutics position peaked at $2.44M in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2025.

Based on Wakefield Asset Management's 13F filing for Q2 2025, filed 5 Aug 2025.